NASDAQ:QLGN - Qualigen Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.50
  • Forecasted Upside: 357.75 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.42
▼ -0.02 (-1.39%)

This chart shows the closing price for QLGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Qualigen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QLGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QLGN

Analyst Price Target is $6.50
▲ +357.75% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Qualigen Therapeutics in the last 3 months. The average price target is $6.50, with a high forecast of $6.50 and a low forecast of $6.50. The average price target represents a 357.75% upside from the last price of $1.42.

This chart shows the closing price for QLGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Qualigen Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/3/2021Alliance Global PartnersLower Price TargetBuy$9.50 ➝ $6.50Low
8/25/2020Alliance Global PartnersUpgradeNeutral ➝ BuyHigh
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Qualigen Therapeutics logo
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.
Read More

Today's Range

Now: $1.42
Low: $1.40
High: $1.44

50 Day Range

MA: $1.57
Low: $1.18
High: $1.88

52 Week Range

Now: $1.42
Low: $1.16
High: $5.47

Volume

163,700 shs

Average Volume

923,989 shs

Market Capitalization

$41.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Qualigen Therapeutics?

The following sell-side analysts have issued reports on Qualigen Therapeutics in the last year: Alliance Global Partners.
View the latest analyst ratings for QLGN.

What is the current price target for Qualigen Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Qualigen Therapeutics in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 357.7%. Alliance Global Partners has the highest price target set, predicting QLGN will reach $6.50 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $6.50 for Qualigen Therapeutics in the next year.
View the latest price targets for QLGN.

What is the current consensus analyst rating for Qualigen Therapeutics?

Qualigen Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QLGN will outperform the market and that investors should add to their positions of Qualigen Therapeutics.
View the latest ratings for QLGN.

What other companies compete with Qualigen Therapeutics?

How do I contact Qualigen Therapeutics' investor relations team?

Qualigen Therapeutics' physical mailing address is 2042 Corte Del Nogal, Carlsbad CA, 92011. The company's listed phone number is (310) 203-1000 and its investor relations email address is [email protected] The official website for Qualigen Therapeutics is www.qualigeninc.com.